KR101297354B1 - 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 - Google Patents
안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 Download PDFInfo
- Publication number
- KR101297354B1 KR101297354B1 KR1020110003334A KR20110003334A KR101297354B1 KR 101297354 B1 KR101297354 B1 KR 101297354B1 KR 1020110003334 A KR1020110003334 A KR 1020110003334A KR 20110003334 A KR20110003334 A KR 20110003334A KR 101297354 B1 KR101297354 B1 KR 101297354B1
- Authority
- KR
- South Korea
- Prior art keywords
- dexibuprofen
- transparent
- syrup composition
- mixtures
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 title claims abstract description 48
- 229960003428 dexibuprofen Drugs 0.000 title claims abstract description 48
- 239000006188 syrup Substances 0.000 title claims abstract description 36
- 235000020357 syrup Nutrition 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 63
- 235000019640 taste Nutrition 0.000 title description 12
- 230000000873 masking effect Effects 0.000 title 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000001329 FEMA 3811 Substances 0.000 claims description 4
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 claims description 4
- 235000010434 neohesperidine DC Nutrition 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229940044476 poloxamer 407 Drugs 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 8
- 238000004062 sedimentation Methods 0.000 abstract description 4
- 230000008021 deposition Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 abstract description 3
- 230000032798 delamination Effects 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000000879 neohesperidine DC Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229960001786 megestrol Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- -1 and in particular Chemical compound 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
도 2는 실시예 1 조성물과 비교예 1의 pH 6.8 용출용매에서의 덱시부프로펜 용출률을 나타낸 것이다.
도 3은 실시예 1 조성물과 비교예 1의 정제수 용출용매에서의 덱시부프로펜 용출률을 나타낸 것이다.
도 4는 실시예 1과 비교예 1의 투명 시럽제 조성물 및 시판제제의 층분리 실험 결과를 나타낸 것이다.
구성 성분 (g) |
실 시 예 1 |
실 시 예 2 |
실 시 예 3 |
실 시 예 4 |
실 시 예 5 |
실 시 예 6 |
비 교 예 2 |
비 교 예 3 |
비 교 예 4 |
비 교 예 5 |
비 교 예 6 |
비 교 예 7 |
비 교 예 8 |
비 교 예 9 |
|
활성성분 | 덱시부프로펜 (입자크기 1 내지 20㎛) |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
1.2 |
유화제 | 플록사머 188 |
5 | 5 | 5 | 8 | 5 | 5 | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
라우릴황산 나트륨 |
- | - | - | - | - | - | 5 | - | - | - | - | - | - | - | |
투명용액안정화제 | 베타싸이클로텍스트린 |
0.6 |
- |
0.6 |
0.6 |
1 |
- |
0.6 |
- |
- |
0.6 |
0.6 |
0.6 |
0.6 |
0.6 |
스테비오 사이드 |
- | 0.6 | - | - | - | 5 | - | - | - | - | - | - | - | - | |
자일리톨 | - | - | - | - | - | - | - | 0.6 | - | - | - | - | - | - | |
아스파탐 | - | - | - | - | - | - | - | - | 0.6 | - | - | - | - | - | |
감미제 |
백당 | 30 | 30 | 50 | 30 | 25 | 25 | 30 | 30 | 30 | - | - | 10 | 60 | 30 |
고과당 | - | - | - | - | - | - | - | - | - | 30 | - | - | - | - | |
D-소르 비톨액 |
- | - | - | - | - | - | - | - | - | - | 30 | - | - | - | |
네오헤스 페리딘 디히드로칼콘 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
- |
|
p H 조절제 |
구연산수화물 및 구연산나트륨 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
적 량 |
정제수 | 정제수를 가하여 총 100mL로 용액으로 제조 |
구 분 | 침점 및 성상 평가 | |
침전생성여부 | 투명여부 | |
실시예 1 | - | - |
실시예 2 | - | - |
실시예 3 | - | - |
실시예 4 | - | - |
실시예 5 | - | - |
실시예 6 | - | - |
비교예 2 | - | + |
비교예 3 | + | - |
비교예 4 | + | - |
비교예 5 | + | - |
비교예 6 | - | + |
비교예 7 | - | - |
비교예 8 | + | + |
비교예 9 | - | - |
- : 침전 없음, 투명함, + : 침전 있음, 불투명함 |
맛의 정도 표기 | 맛의 느낌 |
1 | 매우 쓰거나 떫은 잔류감이 있다. |
2 | 약간 쓰거나 떫은 잔류감이 있다. |
3 | 쓴 맛과 잔류감이 없다. |
4 | 떫은 잔류감이 없고 약간 달다. |
5 | 떫은 잔류감이 전혀 없고 달고 맛있다. |
구 분 | 맛의 정도 평가 |
실시예 1 | 4.5 |
실시예 2 | 2.6 |
실시예 3 | 3.8 |
실시예 4 | 2.3 |
실시예 5 | 3.7 |
실시예 6 | 4.0 |
실시예 7 | 3.5 |
비교예 1 | 1.4 |
비교예 7 | 1.0 |
비교예 9 | 1.3 |
시험항목 |
시험기간 | ||||
초기 | 1개월 | 2개월 | 4개월 | 6개월 | |
성상 (변색) | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 |
성상 (층분리/침전) |
변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 |
pH | 4.25 | 4.21 | 4.25 | 4.27 | 4.23 |
함량 | 101.0% | 101.3% | 101.1% | 100.8% | 101.2% |
총 유연물질 | 불검출 | 불검출 | 불검출 | 불검출 | 불검출 |
시험항목 |
시험기간 | ||||
초기 | 1개월 | 2개월 | 4개월 | 6개월 | |
성상 (변색) | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 |
성상 (층분리/침전) |
변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 | 변화없슴 |
pH | 4.25 | 4.20 | 4.26 | 4.25 | 4.22 |
함량 | 101.0% | 103.6% | 98.5% | 99.1% | 99.7% |
총 유연물질 | 불검출 | 불검출 | 불검출 | 불검출 | 불검출 |
Claims (6)
- 평균입자크기가 1 내지 20㎛인 덱시부프로펜 0.5 내지 10.0 w/v%;
베타싸이클로덱스트린, 스테비오사이드 및 이들의 혼합물로 이루어진 군에서 선택된 투명용액안정화제 0.25 내지 5.0 w/v%;
폴록사머188, 폴록사머407 및 이들의 혼합물로 이루어진 군에서 선택된 유화제 3.0 내지 10.0 w/v%;
네오헤스페리딘 디히드로칼콘 0.01 내지 1 w/v%;
백당 20.0 내지 50.0 w/v%;
정제수 30.0 내지 70.0 w/v%; 및
pH 조절제 0.1 내지 10.0w/v%를 포함하고,
pH 2.0 내지 8.0인 것을 특징으로 하는 투명한 덱시부프로펜 시럽제 조성물. - 삭제
- 제 1 항에 있어서,
상기 pH 조절제가 구연산수화물, 구연산나트륨수화물 및 이들의 혼합물로 이루어진 군에서 선택된 것을 특징으로 하는 투명한 덱시부프로펜 시럽제 조성물. - 삭제
- 삭제
- 제 1 항에 기재된 투명한 덱시부프로펜 시럽제 조성물의 제조방법으로서,
덱시부프로펜; 베타싸이클로덱스트린, 스테비오사이드 및 이들의 혼합물로 이루어진 군에서 선택된 투명용액안정화제; 및 네오헤스페리딘 디히드로칼콘을 혼합하는 단계(1공정);
정제수에 폴록사머188, 폴록사머407 및 이들의 혼합물로 이루어진 군에서 선택된 유화제; 구연산수화물, 구연산나트륨수화물 및 이들의 혼합물로 이루어진 군에서 선택된 pH 조절제; 보존제; 및 백당을 넣은 다음 70 내지 90℃에서 1 내지 3시간 교반하면서 가열하여 용해시키는 단계(2공정);
공정2 용액에 공정1의 혼합물을 첨가한 다음 70 내지 90℃에서 1 내지 3시간 교반하면서 가열하여 용해시키는 단계(3공정);
공정3 용액을 30 내지 35℃로 냉각시키는 단계(4공정);
를 포함하는 것을 특징으로 하는 투명한 덱시부프로펜 시럽제 조성물의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110003334A KR101297354B1 (ko) | 2011-01-13 | 2011-01-13 | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110003334A KR101297354B1 (ko) | 2011-01-13 | 2011-01-13 | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120082061A KR20120082061A (ko) | 2012-07-23 |
KR101297354B1 true KR101297354B1 (ko) | 2013-08-19 |
Family
ID=46713957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110003334A Active KR101297354B1 (ko) | 2011-01-13 | 2011-01-13 | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101297354B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104173277A (zh) * | 2013-05-23 | 2014-12-03 | 上海博悦生物科技有限公司 | 一种右旋布洛芬口服液体制剂及其制备方法 |
WO2014194872A1 (en) | 2013-06-04 | 2014-12-11 | Zentiva, K.S. | Taste masking of water soluble drugs using poloxamers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004515478A (ja) * | 2000-12-04 | 2004-05-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | 改善された経口認容性を有する薬剤処方 |
KR20050071889A (ko) * | 2004-01-05 | 2005-07-08 | 신일제약주식회사 | 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물 |
KR20060079880A (ko) * | 2005-01-03 | 2006-07-07 | 한미약품 주식회사 | 활성 성분으로 덱시부프로펜을 함유하는 시럽제 조성물 및그의 제조 방법 |
-
2011
- 2011-01-13 KR KR1020110003334A patent/KR101297354B1/ko active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004515478A (ja) * | 2000-12-04 | 2004-05-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | 改善された経口認容性を有する薬剤処方 |
KR20050071889A (ko) * | 2004-01-05 | 2005-07-08 | 신일제약주식회사 | 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물 |
KR20060079880A (ko) * | 2005-01-03 | 2006-07-07 | 한미약품 주식회사 | 활성 성분으로 덱시부프로펜을 함유하는 시럽제 조성물 및그의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20120082061A (ko) | 2012-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0161969B1 (ko) | 실질적으로 수불용성인 약제학적 활성 성분을 위한 약제학적 수성 현탁액 조성물 | |
US8263652B2 (en) | Stabilized pediatric suspension of carisbamate | |
KR101490721B1 (ko) | 감칠맛을 가진 디페리프론용 액상 제제 | |
KR101551506B1 (ko) | 레바미피드를 함유하는 의약 조성물 | |
EP0379753B1 (de) | N-Acetylglucosamin-Zubereitungen zur buccalen Anwendung | |
CA2011063C (en) | Nicardipine pharmaceutical composition for parenteral administration | |
EP2741750A1 (en) | Pharmaceutical composition comprising cefuroxime | |
JP2818220B2 (ja) | 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法 | |
EP4061333B1 (en) | Injectable compositions of ursodeoxycholic acid | |
KR20240105361A (ko) | L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법 | |
KR20040074052A (ko) | 증가된 용해도를 갖는 플라바노리그난 제제 | |
KR101431069B1 (ko) | 펠라고니움 시도이데스 추출물 및 레보드로프로피진을 포함하는 시럽 | |
KR101297354B1 (ko) | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 | |
JP6410814B2 (ja) | フェキソフェナジンを含む経口投与用液体医薬組成物 | |
EP3644967B1 (en) | A stable aqueous hydroxycarbamide solution | |
JP4889948B2 (ja) | 服用感に優れた内服液剤 | |
JPH0473411B2 (ko) | ||
JPH11171793A (ja) | ビタミンb1類配合液剤 | |
JP3995202B2 (ja) | 経口用ウコン類組成物 | |
WO2012150607A2 (en) | Oral liquid composition comprising divalproex sodium and process for preparing thereof | |
KR102556874B1 (ko) | 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법 | |
KR20200111138A (ko) | 용해성 및 안정성이 향상된 덱시부프로펜 시럽제제 | |
KR20190093999A (ko) | 용해성 및 안정성이 향상된 덱시부프로펜 시럽제제 | |
JP2002536401A (ja) | メタミゾール含有起泡性医薬組成物 | |
JPH08333268A (ja) | カンゾウの抽出物を配合した安定な液剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20110113 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130111 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130722 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130809 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130812 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20160809 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20160809 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170807 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20170807 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180709 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20180709 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190730 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20190730 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20200910 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20211012 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20221027 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20230808 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20240620 Start annual number: 12 End annual number: 12 |